Cartesian Therapeutics
RNAC
81 hedge funds and large institutions have $174M invested in Cartesian Therapeutics in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 19 closing their positions.
132% more call options, than puts
Call options by funds: $183K | Put options by funds: $79K
118% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 11
105% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 19
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
33% more funds holding
Funds holding: 61 → 81 (+20)
28% more capital invested
Capital invested by funds: $136M → $174M (+$37.9M)
0.16% more ownership
Funds ownership: 2.18% → 2.34% (+0.16%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$14.2M |
| 2 |
BlackRock
New York
|
+$9.86M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$8.62M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.6M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$16.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$11.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.09M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.68M |
| 5 |
Millennium Management
New York
|
-$2.53M |
RNAC Hedge Fund Activity: Q2 2020 in Review
81 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2020, worth a combined $174M — up 28% from $136M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RNAC positions and 19 closed out — a net gain of 20 holders — while 24 added to existing stakes and 11 trimmed.
The largest buyer was BVF Inc, adding an estimated $14.2M. The largest seller was Vivo Capital, cutting an estimated $16.9M.
- 81 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2020, up from 61 in Q1 2020.
- Funds reported $174M of Cartesian Therapeutics stock for Q2 2020, up 28% quarter-over-quarter.
- 39 funds opened new Cartesian Therapeutics positions in Q2 2020 and 19 closed out, a net change of +20 holders.
- The largest Cartesian Therapeutics buyer in Q2 2020 was BVF Inc, an estimated $14.2M added.
- The largest Cartesian Therapeutics seller in Q2 2020 was Vivo Capital, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2020.